Barry Coller, MD
Barry Coller, MD is the David Rockefeller Professor of Medicine; Head, Laboratory of Blood and Vascular Biology; Physician-in-Chief of The Rockefeller University Hospital; and Vice President for Medical Affairs at The Rockefeller University.
Although in-hospital mortality of ST segment-elevated acute myocardial infarction (STEMI) has decreased dramatically, we have done little to decrease pre-hospital mortality, which now accounts for ~50% of STEMI deaths and significant irreversible loss of myocardium.
To improve pre-hospital therapy, Dr. Coller developed RUC-4, a novel αIIbβ3 antagonist optimized for intramuscular (IM) administration by autoinjector. Unlike current small molecule antagonists, it does not induce the active conformation of the receptor and thus may have better efficacy and be less likely to induce thrombocytopenia.
Dr. Coller’s research interests have focused on hemostasis and thrombosis, in particular platelet physiology. He developed a monoclonal antibody that inhibits platelet function and a derivative of that antibody (abciximab; ReoPro™; Centocor/Eli Lilly) was approved for human use by the FDA in 1994.
Dr. Coller received his BA from Columbia University and his MD from the New York University School of Medicine. He did his residency on internal medicine at Bellvue Hospital in New York City and advanced training in hematology and clinical pathology at the National Institutes of Health.